Evidence supporting the use of: Omega-3
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been explored as a potential adjunct therapy in Parkinson's Disease (PD) due to their anti-inflammatory and neuroprotective properties observed in preclinical studies. Experimental models suggest that omega-3s can reduce neuroinflammation, oxidative stress, and neuronal apoptosis, all of which are implicated in the progression of PD. Some small human studies and pilot trials have investigated omega-3 supplementation in people with Parkinson's Disease. For example, a 2008 randomized controlled trial (RCCT) by da Silva et al. found that omega-3 supplementation, alongside standard antidepressant therapy, improved depressive symptoms in PD patients over 12 weeks. However, the trial did not demonstrate a significant benefit in core motor symptoms of the disease. Other clinical trials have been small, short-term, or inconclusive regarding omega-3's impact on disease progression or motor function, and systematic reviews conclude that evidence for omega-3 supplementation as a disease-modifying treatment in PD is limited and inconsistent. No major clinical guidelines recommend omega-3s specifically for PD management. While omega-3s are generally regarded as safe and may support overall brain and cardiovascular health, robust evidence supporting their efficacy for Parkinson’s Disease specifically remains insufficient. More large-scale, long-term randomized controlled trials are needed to clarify their role in PD.

More about Omega-3
More about Parkinson's Disease

Products containing Omega-3

We currently have no products on Vitabase that contain this ingredient.